Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 7 of 11, showing 5 Applications out of 53 total, starting on record 31, ending on 35

# Protocol No Study Title Investigator(s) & Site(s)

31.

ECCT/19/11/03   A Pilot BE study for Enalpril 5mg
    A bioequivalent pilot study of a locally-produced brand of enalapril tablets:  a key step towards implementation of bioequivalent study regulatory requirements in East Africa   
Principal Investigator(s)
1. Simon Njoroge Njenga
Site(s) in Kenya
Kenya Medical Research Institute
 
View

32.

ECCT/19/03/01   Validation of syringe extension device
    Validation of re-usable, low cost syringe extension device for the provision of paracervical analgesia during gynecological procedures   
Principal Investigator(s)
1. Stephen Gwer
2. Aparna Ramanathan
Site(s) in Kenya
1. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
2. Kisumu County Hospital (Kisumu county)
3. God\'s Will Clinic (Kisumu county)
4. Marie Stopes Kenya-Kisumu Clinic (Kisumu county)
 
View

33.

ECCT/14/11/02   A5297
    An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium falciparum Subclinical Parasitemia in HIV-infected Adults with CD4+ Counts >200 and < 500 cells/mm3   
Principal Investigator(s)
1. VICTOR AKELO
Site(s) in Kenya
KEMRI/CDC CLINICAL RESEARCH CENTRE
 
View

34.

ECCT/23/11/02   CROSSWALK Acute (A)
    A PHASE IB, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO‑OCCLUSIVE EPISODES (VOE) IN PATIENTS WITH SICKLE CELL DISEASE (SCD)   
Principal Investigator(s)
1. Fredrick Chite Asirwa
Site(s) in Kenya
1. In this submission: International Cancer Institute (Uasin Gishu county)
 
View

35.

ECCT/11/12/04   PENNVAX-G DNA/MVA HIV Vaccine Phase 1 trial
    A Phase I Study of the Safety and Immunogenicity of PENNVAX™-G DNA (Env & Gag) Administered by Intramuscular Biojector® 2000 or by CELLECTRA® Intramuscular Electroporation Device Followed by MVACMDR (HIV-1 CM235 env/ CM240 gag/pol) Boost in Healthy, HIV Uninfected Adults   
Principal Investigator(s)
1. FREDRICK KIPYEGO SAWE
Site(s) in Kenya
KEMRI/Walter Reed Project-Kericho
 
View